Tirzepatide to Dulaglutide Dose Conversion Guide

Why Patients Switch from Tirzepatide to Dulaglutide

Tirzepatide, sold as Mounjaro, is a dual GIP and GLP-1 receptor agonist, meaning it activates two separate hormone pathways that regulate blood sugar and appetite. Dulaglutide, sold as Trulicity, activates only the GLP-1 pathway. That mechanistic difference makes this transition more than a simple medication swap.

Patients switch for a variety of practical reasons. Insurance formulary changes are among the most common, particularly as payers update their preferred drug lists. Supply shortages, cost differences, or side effect intolerance also prompt transitions. Whatever the reason, understanding why the two drugs are not interchangeable on paper is the first step toward a safe switch.

Because tirzepatide's GIP receptor activity adds a layer of blood sugar and weight control that dulaglutide cannot fully replicate, patients should expect some difference in outcomes after the change. Setting realistic expectations before the switch helps patients stay engaged with monitoring rather than becoming discouraged by early glucose fluctuations.

Why No Direct Dose Conversion Table Exists

Many patients search for a simple chart that maps their tirzepatide dose to a dulaglutide milligram equivalent. No such FDA-approved or clinically validated conversion table exists. The two drugs differ not only in potency but in the number of receptors they engage, making any milligram-to-milligram comparison fundamentally incomplete.

Clinicians rely on clinical judgment rather than a fixed formula. They consider current A1C values, recent blood glucose trends, body weight, kidney function, and whether the patient is also taking sulfonylureas or insulin. A numeric conversion would ignore all of these variables and could lead to either underdosing, which risks hyperglycemia, or overdosing, which increases the chance of GI side effects.

This is also why online dose calculators for this specific switch should be viewed with caution. They may offer a rough starting point for a conversation with your provider, but they are not a substitute for individualized clinical review.

Understanding the Dose Ranges of Each Drug

Knowing the available doses for each medication helps frame what is and is not possible when transitioning. The table below outlines the weekly dose options and provides general clinical guidance on suggested starting points. These are approximate clinical conventions, not prescriptive rules.

Tirzepatide is available in six weekly doses ranging from 2.5 mg to 15 mg. Dulaglutide offers four weekly doses topping out at 4.5 mg. The ceiling on dulaglutide dosing means patients at the higher end of tirzepatide therapy may find that even the maximum dulaglutide dose does not fully replicate their previous level of control.

General Clinical Approach to the Transition

Most clinicians do not attempt to find a numeric match. Instead, they begin with a conservative dulaglutide dose and titrate upward every four to eight weeks based on blood glucose readings and tolerance.

Patients who were on low tirzepatide doses, roughly 2.5 mg to 5 mg weekly, are commonly started on dulaglutide 0.75 mg or 1.5 mg. This cautious approach limits the risk of GI side effects during the adjustment period, even though these patients may have already tolerated GLP-1 therapy for some time.

Patients coming from higher tirzepatide doses, 10 mg to 15 mg weekly, may be started at 3 mg or 4.5 mg dulaglutide with the understanding that full glycemic equivalence is unlikely. These patients benefit from early, honest conversations with their clinician about the possibility of needing additional diabetes medications to close any gaps in blood sugar control.

The timing of the switch also matters. Most providers plan the first dulaglutide injection for the week following the last tirzepatide dose. This approach avoids overlapping drug activity while minimizing the gap in coverage.

What to Expect in the Weeks After Switching

Blood glucose levels often rise modestly in the first few weeks after the switch, even in patients who had excellent control on tirzepatide. This is a predictable consequence of moving to a single-receptor drug and is not necessarily a sign that dulaglutide is failing. Patience and consistent monitoring matter during this window.

Weight changes are another area where expectations should be calibrated carefully. Dulaglutide produces meaningful but generally smaller weight reductions compared to tirzepatide. Patients who experienced significant weight loss on tirzepatide may see some of that weight return. Adjusting dietary habits and increasing physical activity during the transition can reduce this effect.

GI side effects, including nausea and occasional vomiting, may reappear even in patients who tolerated tirzepatide without issue. The two drugs share a GLP-1 mechanism but have different molecular structures, and the body may respond differently at the GI level. Starting at a lower dulaglutide dose is one way to reduce this risk.

Monitoring Plan During the Transition Period

Proactive monitoring is the most reliable way to catch problems early. Patients should aim for daily or twice-daily self-monitoring of blood glucose for at least four weeks after switching. This increased frequency gives both the patient and clinician the data needed to make timely dose adjustments.

A follow-up A1C test at three months after the switch is the standard checkpoint for evaluating whether dulaglutide is providing adequate glycemic coverage. If A1C has risen meaningfully, the clinician may choose to titrate dulaglutide upward or add a complementary medication.

Patients should also keep a simple log of injection-site reactions, nausea episodes, and any low blood sugar events, particularly if they are also taking a sulfonylurea or insulin. Hypoglycemia risk increases when multiple glucose-lowering agents are combined, and early documentation helps clinicians adjust regimens quickly.

Doctronic's 24/7 platform, which has completed more than 22 million AI consultations, makes it straightforward to report these symptoms between scheduled appointments and get timely guidance from a licensed clinician without waiting for a callback.

Frequently Asked Questions

What is the dulaglutide equivalent of 5 mg tirzepatide?

There is no exact equivalent. Patients coming from 5 mg tirzepatide are often started on dulaglutide 0.75 mg or 1.5 mg weekly to limit GI side effects, then titrated based on blood sugar response and A1C. Your clinician will tailor the starting dose to your specific history and current glycemic control.

Can I switch from tirzepatide to dulaglutide on the same day?

Technically yes, since both are weekly injections. Most clinicians plan the switch so that dulaglutide begins the week after the last tirzepatide dose. Same-day switching may be used in urgent situations, but the timing should be confirmed with your prescriber to avoid overlapping effects and unnecessary side effects.

Will dulaglutide control my blood sugar as well as tirzepatide did?

Possibly, but not always. Tirzepatide activates both GIP and GLP-1 receptors, while dulaglutide activates only GLP-1 receptors. This difference means some patients experience a modest rise in blood glucose after switching. Close monitoring and dose titration over several weeks can help minimize the gap in control.

Does switching from tirzepatide to dulaglutide cause weight gain?

Weight gain is possible, though not guaranteed. Dulaglutide typically produces less weight loss than tirzepatide. Patients who had significant weight loss on tirzepatide may see some weight return. Adjusting diet and physical activity during the transition can help manage this expected difference in the medications' effects.

How long does it take for dulaglutide to reach full effectiveness after switching?

Dulaglutide generally reaches steady-state blood levels within two to four weeks, but meaningful A1C changes take closer to eight to twelve weeks. A three-month follow-up appointment gives your clinician enough data to decide whether the current dulaglutide dose is sufficient or needs to be increased.

The Bottom Line

Switching from tirzepatide to dulaglutide is not a simple swap. Because tirzepatide activates both GIP and GLP-1 receptors while dulaglutide targets only GLP-1 receptors, there is no reliable milligram-to-milligram conversion. Your starting dulaglutide dose should be based on your personal A1C, glycemic history, and tolerability, factors that only a clinician reviewing your full medical record can properly weigh. Doctronic, which has conducted over 22 million AI consultations with 99.2% treatment plan alignment with board-certified physicians, offers same-day access to licensed clinicians who can review your dose history and build a safe, individualized transition plan. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.